Table 2

Mortality from outcomes of interest in the full cohort and by department (1950 to 2016, US referent rates^*)

Underlying cause (ICD-10 codes)	All			San Francisco			Chicago			Philadelphia			Heterogeneity
Underlying cause (ICD-10 codes)	Obs	SMR	95% CI	Obs	SMR	95% CI	Obs	SMR	95% CI	Obs	SMR	95% CI	P value
All causes	14 057	0.97	0.95 to 0.98	2391	0.80	0.77 to 0.83	6972	1.02	1.00 to 1.05	4694	0.99	0.97 to 1.02	< 0.01
All cancers^C00-C97	3843	1.12	1.08 to 1.16	655	0.95	0.88 to 1.02	1960	1.20	1.15 to 1.26	1228	1.11	1.04 to 1.17	< 0.01
MN oesophagus^C15	133	1.31	1.10 to 1.55	26	1.31	0.86 to 1.92	68	1.39	1.08 to 1.77	39	1.18	0.84 to 1.62	0.71
MN stomach^C16	124	1.06	0.88 to 1.27	27	1.13	0.75 to 1.65	62	1.15	0.88 to 1.48	35	0.90	0.62 to 1.25	0.46
MN intestine^C17-C18	370	1.27	1.14 to 1.40	59	0.99	0.75 to 1.27	189	1.37	1.19 to 1.58	122	1.28	1.07 to 1.53	0.08
MN rectum^C19-C21	97	1.32	1.07 to 1.61	20	1.33	0.81 to 2.06	52	1.53	1.14 to 2.01	25	1.02	0.66 to 1.51	0.25
MN lung^C33-C34	1197	1.08	1.02 to 1.15	154	0.71	0.60 to 0.83	638	1.20	1.11 to 1.30	405	1.14	1.03 to 1.26	< 0.01
MN breast^C50	10	1.24	0.59 to 2.27	NR	2.11	0.58 to 5.41	NR	1.16	0.38 to 2.71	NR	0.53	0.01 to 2.94	0.37
MN prostate^C61	334	1.08	0.97 to 1.20	60	0.89	0.68 to 1.15	176	1.23	1.05 to 1.42	98	0.99	0.81 to 1.21	0.06
MN other male genital^{C60, C62-C63}	<5	0.39	0.11 to 1.00	<5	0.52	0.01 to 2.90	0	NC	NC	<5	0.85	0.18 to 2.49	0.15
MN kidney^C64-C66	108	1.22	1.00 to 1.47	15	0.85	0.48 to 1.40	66	1.57	1.22 to 2.00	27	0.93	0.61 to 1.36	0.02
MN bladder^C67-C68	104	0.98	0.80 to 1.18	23	1.01	0.64 to 1.52	48	0.98	0.72 to 1.30	33	0.96	0.66 to 1.34	0.98
MN skin^{C43-C44, C46.0, C46.9}	78	1.05	0.83 to 1.31	18	1.21	0.72 to 1.92	35	1.00	0.70 to 1.39	25	1.02	0.66 to 1.51	0.79
Mesothelioma^C45	18	1.86	1.10 to 2.94	<5	2.00	0.54 to 5.12	10	2.14	1.03 to 3.93	<5	1.33	0.36 to 3.40	0.71
MN brain^{C47, C70-C72}	86	0.99	0.79 to 1.23	20	1.21	0.74 to 1.87	37	0.89	0.63 to 1.23	29	1.01	0.68 to 1.45	0.55
NHL^{C46.3, C82-C85, C88.0, C88.3, C91.4, C96}	151	1.21	1.03 to 1.42	30	1.19	0.80 to 1.70	66	1.11	0.86 to 1.41	55	1.37	1.03 to 1.78	0.51
Leukemia^{C91.0-C91.3, C91.5-C91.9, C92-C95}	150	1.11	0.94 to 1.31	26	0.94	0.62 to 1.38	75	1.18	0.93 to 1.48	49	1.12	0.83 to 1.48	0.61
Multiple myeloma^{C88.7, C88.9, C90}	54	0.93	0.70 to 1.21	12	1.03	0.53 to 1.79	24	0.86	0.55 to 1.27	18	0.97	0.58 to 1.54	0.85
Ischaemic heart disease^{I20-I22, I24-I25, I51.3, I51.6}	3945	0.98	0.95 to 1.01	640	0.76	0.70 to 0.82	2003	1.08	1.04 to 1.13	1302	0.98	0.93 to 1.03	< 0.01
Cerebrovascular disease^{G45.0-G45.2, G45.4-G45.9, I60-I69}	725	0.90	0.83 to 0.97	145	0.83	0.70 to 0.97	341	0.93	0.84 to 1.04	239	0.90	0.79 to 1.02	0.48
COPD^J40-J44	491	0.78	0.71 to 0.85	72	0.54	0.43 to 0.68	268	0.91	0.80 to 1.03	151	0.75	0.64 to 0.88	< 0.01
Cirrhosis & other chronic liver disease^{K70, K73-K74, K76.0}	321	1.16	1.03 to 1.29	71	1.37	1.07 to 1.73	156	1.16	0.98 to 1.35	94	1.03	0.84 to 1.27	0.19

Findings in bold font are statistically significant with a 95% confidence interval that excludes 1.0.
*Stratified by age (5 year intervals), gender, race (white/other) and calendar period (5 year intervals).
COPD, chronic obstructive pulmonary disease; ICD, International Classification of Diseases; MN, malignancy; NC, not calculated; NHL, non-Hodgkin's lymphoma; NR, not reported to avoid disclosing numbers less than 5; Obs, observed; SMR, standardised mortality ratio.